Last updated: September 8, 2026
ARCALYST (rilonacept) has shifted from a niche cryopyrin-associated periodic syndrome therapy into a commercial immunology product driven by recurrent pericarditis. Kiniksa Pharmaceuticals owns the commercial franchise and has expanded revenue through increased diagnosis, chronic maintenance use, and adoption of a once-weekly regimen. The principal risks are payer control, treatment-duration variability, competition from low-cost anti-inflammatory therapies, and the eventual loss of exclusivity without a conventional small-molecule generic pathway.
What is ARCALYST and which diseases does it treat?
ARCALYST is a recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta by binding IL-1. Regeneron originally developed the product. Kiniksa is responsible for the current commercial franchise under its collaboration with Regeneron.
The U.S. Food and Drug Administration approved ARCALYST in 2008 for:
- Cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
- Deficiency of interleukin-1 receptor antagonist, or DIRA, in patients aged 12 and older.
- Recurrent pericarditis and reduction in the risk of recurrence in adults and adolescents aged 12 and older weighing at least 40 kilograms.
The recurrent-pericarditis approval in March 2021 materially changed the product’s commercial profile. The indication created a larger and more commercially accessible market than the original ultra-rare CAPS population. The FDA based approval on the RHAPSODY Phase 3 study, which showed rapid symptom control and a lower recurrence rate during the randomized withdrawal period.[1]
What is the ARCALYST mechanism of action?
Rilonacept is an interleukin-1 trap. It inhibits signaling from both IL-1 alpha and IL-1 beta, cytokines involved in systemic inflammation and pericardial inflammation. This mechanism differentiates ARCALYST from colchicine, nonsteroidal anti-inflammatory drugs, and corticosteroids, which are commonly used in recurrent pericarditis but do not selectively neutralize IL-1.
The product is administered by subcutaneous injection. The labeled recurrent-pericarditis regimen is a 320-milligram loading dose followed by 160 milligrams once weekly.
How has ARCALYST revenue changed?
ARCALYST revenue has grown sharply since the recurrent-pericarditis launch. Kiniksa’s filings and earnings releases identify ARCALYST as the company’s dominant commercial asset and primary source of product revenue.[2][3]
| Period |
Commercial development |
Reported or disclosed ARCALYST revenue trend |
| 2008-2020 |
CAPS and other rare autoinflammatory indications |
Limited commercial scale |
| 2021 |
Recurrent-pericarditis approval and launch |
Rapid post-approval expansion |
| 2022 |
Broader physician and payer adoption |
Approximately $225 million in net product revenue |
| 2023 |
Continued patient additions and recurring use |
Approximately $309 million in net product revenue |
| 2024 |
Ongoing growth in recurrent pericarditis |
Approximately $400 million-plus annual product revenue, based on company reporting |
Kiniksa’s revenue growth has been driven by several factors:
- Recurrent pericarditis provides a larger addressable population than CAPS.
- The product can be used as chronic maintenance therapy after disease control.
- Patients with multiple recurrences are more likely to justify an expensive targeted biologic.
- The once-weekly maintenance schedule is simpler than repeated short courses of corticosteroids or daily anti-inflammatory treatment.
- Kiniksa has built commercial infrastructure around cardiology, rheumatology, and specialty pharmacy channels.
The revenue trajectory is more important than the absolute patient count. ARCALYST is priced as a specialty biologic, so a relatively small treated population can support hundreds of millions of dollars in annual sales.
What is the market opportunity for ARCALYST?
The addressable market consists of diagnosed recurrent-pericarditis patients who have inadequate response to, cannot tolerate, or cannot safely discontinue conventional therapies. The broader pericarditis population is substantially larger than the population currently receiving ARCALYST, but most patients do not require long-term biologic therapy.
How large is the recurrent-pericarditis market?
Recurrent pericarditis occurs after an initial episode in a meaningful minority of patients. The commercial opportunity is concentrated in patients with repeated recurrences, steroid dependence, persistent inflammation, or substantial treatment toxicity.
The market has three layers:
| Market segment |
ARCALYST opportunity |
| Acute, first-episode pericarditis |
Low; conventional therapy remains standard |
| Recurrent pericarditis responsive to colchicine or NSAIDs |
Moderate; payer and physician barriers limit use |
| Refractory, steroid-dependent, or frequently recurring disease |
Highest; strongest clinical and economic rationale |
ARCALYST is therefore a targeted second-line or later-line therapy rather than a universal pericarditis treatment. Its commercial ceiling depends on identifying patients with sufficiently severe disease and securing reimbursement for long-term use.
What is the FDA regulatory status of ARCALYST?
ARCALYST is FDA-approved and commercially available in the United States. Its key regulatory milestones are:
| Milestone |
Date |
| Initial FDA approval for CAPS |
2008 |
| FDA approval for recurrent pericarditis |
March 2021 |
| FDA approval for DIRA |
2020 |
| RHAPSODY Phase 3 data supporting recurrent-pericarditis approval |
2020-2021 |
The recurrent-pericarditis indication received orphan-drug treatment. Orphan exclusivity generally runs for seven years from approval for the protected indication, subject to statutory exceptions. The recurrent-pericarditis orphan-exclusivity period therefore began in March 2021 and is expected to run through March 2028.[1][4]
Regulatory exclusivity does not prevent all competing products from entering the market. It primarily restricts approval of another product for the same orphan indication when the competing product is considered clinically superior only under limited circumstances.
What patents protect ARCALYST?
ARCALYST is a biologic, so its market protection does not follow the standard small-molecule Orange Book model. FDA-approved biologics are recorded in the Purple Book, while the FDA does not publish an Orange Book-style patent-and-expiration table for biologics.[5]
The relevant protection layers are:
- Biologic regulatory exclusivity.
- Composition and engineered-protein patents.
- Manufacturing and cell-line patents.
- Formulation and stability patents.
- Method-of-use patents covering IL-1 blockade in recurrent pericarditis.
- Contractual rights under the Regeneron-Kiniksa collaboration.
When does ARCALYST lose exclusivity?
The initial 12-year U.S. reference-product exclusivity period for the biologic began with the original 2008 licensure and is no longer the principal barrier to competition. The commercial protection period now depends primarily on patent claims, orphan exclusivity for specific indications, manufacturing complexity, and the absence of an approved biosimilar.
The most commercially relevant regulatory exclusivity date is March 2028 for the recurrent-pericarditis orphan indication. Patent protection may extend beyond that date through indication-specific and formulation-related claims, but the exact enforceable scope depends on issued claims, terminal disclaimers, maintenance fees, and litigation outcomes.
Are ARCALYST patents listed in the Orange Book?
No. ARCALYST is a biologic, and the Orange Book is the FDA’s principal patent-listing system for approved drugs subject to the abbreviated new drug application pathway. Biosimilar competition is governed under the Biologics Price Competition and Innovation Act, not the Hatch-Waxman Orange Book framework.[5][6]
A future biosimilar applicant would generally use the BPCIA patent-information exchange and litigation process rather than submit a conventional Paragraph IV certification against an Orange Book-listed patent.
Are there Paragraph IV challenges to ARCALYST?
No conventional Paragraph IV challenge is expected because ARCALYST is a biologic rather than a small-molecule drug approved under an NDA with Orange Book-listed patents.
A future competitor could pursue:
- A biosimilar application under section 351(k) of the Public Health Service Act.
- A full biologics license application under section 351(a).
- A non-infringing alternative formulation or delivery system.
- A product aimed at a different indication or patient population.
A 351(k) biosimilar applicant would need to demonstrate biosimilarity and could face patent litigation under the BPCIA. The absence of a Paragraph IV pathway reduces the probability of the highly standardized generic-entry process seen with small-molecule products.
Which companies are challenging or competing with ARCALYST?
No approved biosimilar competitor has displaced ARCALYST in the United States. Competition is primarily therapeutic rather than direct.
| Competitor |
Company or originator |
Relevance to ARCALYST |
| Colchicine |
Multiple manufacturers |
Low-cost standard therapy; major payer comparator |
| NSAIDs |
Multiple manufacturers |
Standard acute and recurrent-pericarditis treatment |
| Corticosteroids |
Multiple manufacturers |
Effective but associated with relapse and toxicity |
| Anakinra |
Sobi |
IL-1 receptor antagonist used off-label or in selected inflammatory disease |
| Canakinumab |
Novartis |
IL-1 beta inhibitor; high-cost, limited pericarditis role |
| Future IL-1 inhibitors |
Multiple developers |
Potential mechanism-based competition |
| Future rilonacept biosimilars |
Not yet established |
Long-term erosion risk after patent and regulatory barriers decline |
Anakinra is the most relevant mechanism-level alternative because it also targets the IL-1 pathway. It requires frequent administration and is not approved by the FDA for recurrent pericarditis. ARCALYST’s once-weekly dosing and indication-specific clinical evidence support its differentiation.
How strong is the ARCALYST patent and commercial estate?
The estate is commercially strong in the near term but less insulated than a product with a long remaining composition-of-matter patent.
Strengths
- FDA approval for a differentiated recurrent-pericarditis indication.
- Orphan exclusivity through approximately March 2028.
- Complex biologic manufacturing requirements.
- Limited clinical precedent for a directly substitutable product.
- Physician familiarity from CAPS and inflammatory-disease use.
- Specialty-pharmacy distribution and reimbursement infrastructure.
Weaknesses
- The original biologic regulatory exclusivity period has expired.
- The initial CAPS market is small.
- No long-duration composition-of-matter barrier should be assumed solely from the 2008 approval date.
- Payers can require failure of colchicine, NSAIDs, or corticosteroids before authorization.
- Long-term treatment persistence may vary by recurrence risk and symptom control.
- Biosimilar development remains possible even without a Paragraph IV event.
The most defensible valuation view is that ARCALYST has a strong commercial position through the late 2020s, with increasing sensitivity to patent scope, biosimilar development, payer management, and treatment-duration data after 2028.
What licensing deals affect ARCALYST?
Kiniksa commercializes rilonacept through a collaboration with Regeneron. The relationship gives Kiniksa access to the ARCALYST franchise while preserving economic participation for Regeneron through contractual payments, royalties, or other agreed economics disclosed in company filings.[2][7]
The licensing structure affects profitability in two ways:
- Kiniksa avoids the cost and time required to develop a new biologic from discovery through approval.
- Royalty and milestone obligations reduce the contribution margin relative to a wholly owned product.
The arrangement also gives Regeneron continuing economic exposure to ARCALYST while allowing Kiniksa to fund commercial expansion and lifecycle management.
What litigation and settlement risks affect ARCALYST?
There is no widely established generic-style patent litigation record comparable to major small-molecule blockbusters. The principal future litigation scenarios are:
- BPCIA litigation involving a proposed rilonacept biosimilar.
- Patent disputes over recurrent-pericarditis dosing or treatment duration.
- Challenges to manufacturing, formulation, or protein-engineering claims.
- Disputes over the scope of Kiniksa’s licensed rights from Regeneron.
- Antitrust or access disputes involving reimbursement restrictions or contracting.
A settlement with a biosimilar applicant could establish an agreed launch date before the expiry of relevant patents. The economic value of such a settlement would depend on whether the entrant receives an indication carve-out, an authorized biosimilar arrangement, or a delayed launch date.
What generic and biosimilar launch risks exist?
The risk is more likely to emerge as a gradual biosimilar threat than as an immediate generic launch.
Near-term risk
Through the late 2020s, ARCALYST benefits from:
- Orphan exclusivity for recurrent pericarditis.
- Manufacturing complexity.
- Limited clinical infrastructure among potential biosimilar developers.
- A still-growing treated-patient base.
Medium-term risk
After orphan exclusivity expires, a biosimilar could compete if a developer can justify the cost of analytical, clinical, regulatory, and commercial investment. Biosimilar entry would likely begin with payer-driven substitution rather than automatic pharmacy substitution because biologics are not interchangeable by default.
Long-term risk
Price erosion could accelerate if multiple biosimilars enter, payers adopt preferred-product strategies, and physicians become comfortable with switching stable patients. The impact would be lower if Kiniksa secures strong patent protection for dosing, formulation, or manufacturing and maintains favorable specialty-pharmacy access.
How does ARCALYST compare with other IL-1 therapies?
| Attribute |
ARCALYST |
Anakinra |
Canakinumab |
| IL-1 target |
IL-1 alpha and beta trap |
IL-1 receptor antagonist |
IL-1 beta |
| FDA approval for recurrent pericarditis |
Yes |
No |
No |
| Typical administration |
Once weekly after loading dose |
Frequent subcutaneous dosing |
Infrequent dosing, indication-dependent |
| Evidence in recurrent pericarditis |
Phase 3 RHAPSODY |
Clinical use and smaller studies |
Limited |
| Commercial position |
Established branded therapy |
Off-label alternative |
Narrower inflammatory-disease use |
| Direct substitution risk |
Moderate |
Mechanism-based, not direct |
Low to moderate |
ARCALYST’s strongest competitive advantage is not simply IL-1 inhibition. It is the combination of FDA approval, randomized clinical evidence, weekly administration, and a commercial reimbursement pathway.
What is the investment outlook for ARCALYST?
ARCALYST remains Kiniksa’s principal value driver. The investment case depends on continued growth in recurrent-pericarditis diagnoses, durable treatment persistence, and successful expansion into patients who are inadequately controlled by conventional therapy.
Revenue can continue to grow without a proportional increase in total pericarditis prevalence if Kiniksa improves diagnosis and converts more high-risk patients to chronic maintenance therapy. The main valuation question is whether growth reflects durable patient additions or a temporary launch-related surge.
Key financial variables are:
- Net price after rebates and discounts.
- New patient starts.
- Persistence beyond the initial treatment period.
- Recurrent-pericarditis market penetration.
- Royalty obligations to Regeneron.
- Sales and marketing intensity.
- Post-2028 patent and biosimilar exposure.
- Kiniksa’s ability to diversify beyond ARCALYST.
The product’s revenue concentration creates both operating leverage and portfolio risk. Strong ARCALYST growth can fund Kiniksa’s pipeline, but setbacks in reimbursement, safety, litigation, or commercial uptake would have an outsized effect on corporate results.
Key Takeaways
- ARCALYST is a once-weekly IL-1 inhibitor marketed by Kiniksa Pharmaceuticals.
- Recurrent pericarditis, approved in 2021, is the product’s primary commercial growth engine.
- Annual ARCALYST revenue increased from roughly $225 million in 2022 to approximately $309 million in 2023 and more than $400 million in 2024 based on company disclosures.
- The principal near-term regulatory protection is orphan exclusivity for recurrent pericarditis, expected to run through approximately March 2028.
- ARCALYST is not subject to a conventional Orange Book Paragraph IV challenge because it is a biologic.
- Competition comes mainly from colchicine, NSAIDs, corticosteroids, anakinra, and future IL-1 therapies.
- The post-2028 risk is biosimilar and payer-driven price erosion rather than an immediate generic launch.
- Kiniksa’s commercial value remains highly concentrated in ARCALYST, making product persistence and exclusivity management central to valuation.
FAQs
Is ARCALYST a biologic or a small-molecule drug?
ARCALYST is a biologic fusion protein. It is composed of an IL-1-binding domain linked to an antibody Fc domain and is regulated under the biologics framework.
Can ARCALYST be substituted automatically at the pharmacy?
No. Automatic substitution depends on state law and whether a competing product is designated interchangeable by the FDA. A future biosimilar would not automatically replace ARCALYST solely because it is biosimilar.
How long do patients typically remain on ARCALYST?
Treatment duration varies. Patients with frequent recurrences, steroid dependence, or persistent inflammatory disease are more likely to remain on therapy, while patients with sustained remission may discontinue under physician supervision.
Does ARCALYST have an FDA-approved biosimilar?
No approved U.S. biosimilar for rilonacept has been established in the cited regulatory and company materials.
What is the biggest commercial threat to ARCALYST?
The largest long-term threat is a combination of loss of orphan exclusivity, successful biosimilar development, payer pressure, and improved physician use of lower-cost conventional or alternative IL-1 therapies.
References
- U.S. Food and Drug Administration. (2021). ARCALYST (rilonacept) prescribing information. https://www.accessdata.fda.gov
- Kiniksa Pharmaceuticals, Ltd. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- Kiniksa Pharmaceuticals, Ltd. (2024). Fourth-quarter and full-year 2023 financial results. https://ir.kiniksa.com
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/orphan-drug-designation-and-exclusivity
- U.S. Food and Drug Administration. (2024). Purple Book database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
- Regeneron Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov
